A Novel Variant Of Regenerating Iα Gene (REG) In Type II Diabetics Among Pakistani Targeted Population

Abstract Objective: Regeneration of pancreatic β-cells, is an essential step towards diabetes management. The regenerating (REG) Iα gene is secreted from damaged β-cell for the synthesis of β-cell. This study aimed to identify REG Iα gene polymorphisms and their association with Type II diabetes (T2DM). Methods: Patients (110) with T2DM and age-related controls were selected from PNS Shifa Hospital, Karachi. DNA was extracted PCR was performed and amplified products were sequenced to identify polymorphisms. For six exons of the REG 1a gene, 6 sets of primers were designed. The selected (51) samples were amplified and sequenced for 306 (51x6) times. Odds ratios were calculated through logistic regression analysis. The correlation was used to find an association between REG Iα and diseases. p< 0.05 was considered significant. Results: Blood samples were drawn from 90 finalized patients, including 70 diabetics and 20 controls with an M: F ratio of 12:8. Twenty patients opted to withdraw. The REG Iα and disease duration in type II diabetics showed a negative correlation (r= -0.355, p=0.005). The single nucleotide polymorphisms (SNPs) of eight sites were detected: g.-385T>C, g.-243T>G, g.-145G>A, g.+142A, g.+209G>T, g.+226A>G, g.+2199G>A, g.+2360A>G.  The novel SNP g.-145G>A was found in all patients (controls, T2DM). Among all SNPs, only g.+209G>T showed a positive association (OR= 2.4, p=0.01) with T2DM. Whereas, g.-243T>G showed a positive association (OR=8.06, p=0.0003) with smoking. Conclusion: A novel variant g.-145G>A REG Iα gene was found among all participants. The SNPs g.+209G>T had a significant positive association with T2DM and SNP g.-243T>G showed an increased risk of the disease among smokers

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Chemical ecology of Carpophilus beetles and their yeast symbionts

This thesis is an exciting avenue of research that broadens our understanding of the ecological relationship between microbes and herbivorous insects and applies this knowledge to the development of new "attract and kill" technologies in insect pest management. The outcomes of the research will help improve existing control practices for Carpophilus beetles, which are major pests in Australian horticulture, and pave the way for developing novel tools and practices for monitoring and controlling newly established insect pests

Changes in People’s Mobility Behavior in Greece after the COVID-19 Outbreak

The lockdown and social distancing policies to reduce COVID-19 spread and perceived safety threats of COVID-19 significantly affected people’s travel behavior. Greece has been suffering from the COVID-19 pandemic, and people’s mobility behavior has been greatly affected. This study aims at: (1) exploring the variations in individuals’ trip frequencies by mode and purpose before and after the COVID-19 outbreak; (2) understanding the effects of individual differences (i.e., sociodemographic details) and perceptions towards COVID-19 (i.e., the perceived threats of COVID-19) on people’s mobility behavior changes after the outbreak; (3) underlining the individuals’ perceptions of the COVID-19 threat on the willingness of public transportation usage. Overall, 403 responses were collected in late 2020. A series of random parameter Probit modeling results reveal multiple individual and perception factors affecting the changes in mobility behavior in Greece. The results from structural equation modeling indicate that perceived COVID-19 threats affect the attitudes and subjective norms towards people’s intentions to use public transportation. The results from this study provide valuable insights for transportation authorities to develop effective strategies to manage traffic during the spread of disease for a possible future epidemic

Thermal Viscous Dissipative Couette Flow in a Channel Filled with Porous Medium

The increasing demand for high-performance electronic devices and surge in power density accentuates the need for heat transfer enhancement. In this study, a thermal viscous dissipative Couette flow and Couette-Poiseuille flow in a channel filled with fluid saturated porous medium is looked into. Two cases of thermal boundary condition are considered: constant heat flux is applied on the moving wall while the fixed plate is insulated, and both plates are subjected to constant heat flux. The study would explore the fluid flow and heat transfer phenomenon for Couette flow and Couette-Poiseuille flow in a channel as well as to establish the relationship between the heat convection coefficient and viscous dissipation. A fully developed flow and local thermal equilibrium are assumed in the analysis. An analytical Nusselt number expression is developed for Couette flow and Couette-Poiseuille flow in terms of Brinkman number as a result of this study, thus providing essential information to gauge the thermal performance of a channel. The results obtained without viscous dissipation are in close agreement with published results for Couette flow and CouettePoiseuille flow

Screening of Different Groundnut, Aarachis hypogaea L. (Fabaceae: Fabales) Cultivars Against Red Hairy Caterpillar, Amsacta albistriga W. (Arctiidae: Lepidoptera) Population in Relation to Leaf Infestation, Physico-morphic Characters, Abiotic Factors and Yield

WOS: 000365465700025Field screening of six groundnut cultivars (BARD-92, BARD-699, BARD-479, BAIU-2000, Golden and Chakori) in randomized complete block design with three replications was conducted against red hairy caterpillar (RHC), Amsacta albistriga (Walker), population in relation to leaf infestation, physico-morphic characters (leaf area and plant height), abiotic factors (temperature, rainfall and humidity) and their ultimate impact on yield. Highest RHC population and leaf infestation was observed on BARD-699 and the lowest on BARD-479 throughout the season. Irrespective of plant height, leaf area seemed to effect insect infestation with minimum infestation on BARD-479 with maximum leaf area while minimum was observed on BARD-699 (maximum insect infestation). The plant height of BARD-699 was found to be maximum, whereas minimum plant height was observed on BARD-479. Maximum pod yield was recorded on Bard-479 and minimum of Bard-699. The order of cultivar resistance against RHC population during the whole crop duration was BARD-479 < BARI-2000 < Golden < BARI-92 < Chakori < BARD-699. RHC population showed significant and positive correlation with leaf infestation, and non-significant and negative correlation with leaf area. Non-significant and positive correlation was found among RHC population and plant height, and significant but negative relationship was noted between mean temperature and RHC population. Although effect of rainfall was significant and positive on RHC population, there was significant and positive correlation between relative humidity and population of RHC. A significant and negative correlation between RHC population and yield was recorded. Based on the results, high yielding cultivar Bard-479 was found resistant and low yielding Bard-699 was found susceptible against RHC